Financial Performance - The net profit attributable to shareholders for 2022 was CNY 217,902,483.86, with undistributed profits amounting to CNY 1,584,999,370.12[5]. - The company achieved operating revenue of CNY 1,259,160,685.98 in 2022, representing a year-on-year increase of 9.42%[24]. - Net profit attributable to shareholders was CNY 217,902,483.86, a decrease of 11.82% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 186,487,630.01, down 14.63% year-on-year[24]. - The net cash flow from operating activities increased by 11.85% to CNY 247,329,288.25[24]. - The company's total assets reached CNY 5,298,919,980.32 at the end of 2022, a 9.15% increase from the previous year[24]. - Basic earnings per share decreased to CNY 0.65, down 12.16% from CNY 0.74 in 2021[25]. - The R&D expenditure accounted for 4.83% of operating revenue, an increase of 0.29 percentage points compared to the previous year[25]. - The weighted average return on net assets was 6.24%, a decrease of 1.16 percentage points from 2021[25]. - The company reported a significant decline in investment income from joint ventures compared to the previous year, contributing to the decrease in net profit[25]. Dividend Policy - The company plans to not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2022 fiscal year, opting to carry forward undistributed profits to the next year[5]. - The company has a cash dividend policy that prioritizes cash dividends, with a minimum distribution ratio of 80% for mature companies without major capital expenditures[193]. - The company’s cash dividend policy is designed to protect the rights of minority investors, ensuring transparency and compliance with regulations[195]. Governance and Compliance - The report includes a standard unqualified audit opinion from Rongcheng Accounting Firm, ensuring the accuracy and completeness of the financial statements[5]. - The company has confirmed that all board members were present at the board meeting, ensuring proper governance and oversight[5]. - There are no special arrangements for corporate governance that apply to the company[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and risk management[145]. - The company maintains transparent information disclosure practices, ensuring all investors have equal access to information[148]. - The company’s governance structure complies with relevant laws and regulations, ensuring the legality of meeting procedures and voting results[154]. - The company has not faced any penalties from securities regulatory agencies in the past three years[175]. - The internal control system is strictly implemented, with regular audits conducted by the audit department to ensure compliance and effective execution of internal controls[198]. - The internal control audit report received a standard unqualified opinion, indicating no significant deficiencies were found during the evaluation[199]. Research and Development - The company is actively engaged in research and development of graphene membranes, which are anticipated to enhance performance in water purification applications[15]. - The total R&D investment for the year was approximately ¥60.82 million, representing a 16.47% increase from the previous year's ¥52.21 million, with R&D expenses accounting for 4.83% of total revenue[75]. - The company has applied for a total of 334 patents, including 200 invention patents, 132 utility model patents, and 2 design patents, with 187 patents granted as of December 31, 2022[72]. - The company has established a comprehensive R&D platform based on the "RDPA" system, focusing on research, development, pilot testing, and application[64]. - The company is committed to expanding its R&D efforts as a key part of its growth strategy, supported by institutional guarantees and innovation incentives[64]. - The company has emphasized the importance of intellectual property and patent technology applications, with 32 new patents filed during the reporting period[71]. Operational Strategy - The company is exploring new business models, including Build-Operate-Transfer (BOT) and Transfer-Operate-Transfer (TOT), to enhance operational efficiency and service delivery[15]. - The company has developed a range of membrane products including tubular ceramic membranes, spiral membranes, flat membranes, hollow fiber membranes, and composite ceramic nanofiltration cores, which are widely used in various industries such as pharmaceuticals, food and beverage, and environmental protection[40]. - The company’s business model includes various operational strategies such as EPC, BOT, BT, and TOT, allowing flexibility in meeting user requirements[46]. - The company provides integrated membrane technology solutions, generating revenue through sales of membrane materials, components, and systems, with a focus on long-term stable income from consumable parts[47]. - The company is committed to improving customer satisfaction by optimizing process flows and reducing operational costs through technology upgrades[142]. Market and Industry Trends - The membrane technology application industry is expected to maintain a high gross margin level due to strong market demand and high technical barriers[54]. - The domestic membrane industry is expected to see an increase in application levels and expansion into new fields, driven by advancements in domestic membrane material technology[60]. - The company aims to expand its market presence through innovative water treatment solutions and strategic partnerships in the environmental technology sector[15]. - The market for industrial wastewater reuse is expected to grow by 20% annually, driven by environmental and clean production requirements[138]. - The municipal drinking water purification market is projected to grow at an annual rate of over 15% due to ongoing improvements in municipal water quality[138]. Risks and Challenges - The company has detailed various operational risks and corresponding mitigation measures in the report, emphasizing the importance of risk management[4]. - The company faces risks in market expansion due to differing local policies and intense competition in new markets[94]. - The company’s revenue is closely tied to macroeconomic conditions and environmental policies, which can lead to income volatility[97]. - Accounts receivable are subject to risks due to slow payment from downstream customers and local government financial conditions affecting wastewater treatment fees[93]. - The company is facing risks related to the economic benefits of its fundraising projects, which may not meet expectations due to market environment changes and project delays[104]. Employee and Management - The total number of employees in the parent company and major subsidiaries is 1,159, with 668 in production, 61 in sales, 224 in technology, and 45 in finance[188]. - The company has established a scientific and fair compensation mechanism based on the importance and scarcity of positions, ensuring employee stability and satisfaction[190]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 478.48 million[171]. - The company has implemented a training and development management system to enhance employee skills and promote sustainable development[191]. - The management team includes experienced professionals with extensive backgrounds in investment and technology sectors, contributing to strategic decision-making[170]. Sustainability and ESG - The company emphasizes the importance of ESG, integrating it into its core business operations, viewing it as a cornerstone for sustainable and long-term development[200]. - The company is committed to green development, focusing on pollution prevention, waste reduction, and energy conservation as part of its operational strategy[200]. - The company aims to establish a high-efficiency, clean, low-carbon, and circular green factory as part of its long-term development strategy[200].

Financial Performance - The net profit attributable to shareholders for 2022 was CNY 217,902,483.86, with undistributed profits amounting to CNY 1,584,999,370.12[5]. - The company achieved operating revenue of CNY 1,259,160,685.98 in 2022, representing a year-on-year increase of 9.42%[24]. - Net profit attributable to shareholders was CNY 217,902,483.86, a decrease of 11.82% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 186,487,630.01, down 14.63% year-on-year[24]. - The net cash flow from operating activities increased by 11.85% to CNY 247,329,288.25, mainly due to increased cash received from sales of goods and services[24]. - The company's total assets at the end of 2022 were CNY 5,298,919,980.32, reflecting a 9.15% increase from the previous year[24]. - The weighted average return on net assets decreased to 6.24%, down 1.16 percentage points from the previous year[25]. - Research and development expenses accounted for 4.83% of operating revenue, an increase of 0.29 percentage points compared to the previous year[25]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the financial report, with no significant omissions or misleading statements[4]. - The report emphasizes the importance of corporate governance and the presence of all board members during the meeting[5]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and risk management[145]. - The company maintains transparent information disclosure practices, ensuring all investors have equal access to information[148]. - All proposals at the five shareholder meetings held in 2022 were approved without any rejections[154]. - The company held its first extraordinary general meeting on January 17, 2022, to elect members of the board and supervisory committee[152]. - The annual general meeting on May 11, 2022, approved the 2021 annual report and financial statements[152]. - The company has established specialized committees under the board, including the audit committee and the nomination committee, to enhance governance[180]. Research and Development - The company is actively engaged in research and development of graphene membranes, which are anticipated to enhance performance in water treatment applications[15]. - The company has over 20 R&D projects completed during the reporting period, indicating a strong focus on innovation[36]. - The total R&D investment for the year was approximately ¥60.82 million, an increase of 16.47% from the previous year's ¥52.21 million, representing 4.83% of total revenue[75]. - The company applied for a total of 334 patents by December 31, 2022, including 200 invention patents, and received 187 authorized patents, with 184 remaining valid after three expired[72]. - The company has developed advanced inorganic non-metallic membrane materials with independent intellectual property rights, which can replace imported products and offer superior performance[46]. - The company has established a strong market influence and authority in the membrane technology application field, with significant experience in industrial liquid separation and membrane water treatment[87]. Operational Risks and Mitigation - The company has outlined various operational risks and corresponding mitigation strategies in the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future strategies and plans are subject to investment risks[6]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company faces risks from changes in major customers' production expansion needs, which can lead to fluctuations in operational performance[93]. - The company's revenue is closely tied to macroeconomic conditions and environmental policies, making it susceptible to fluctuations in market demand[97]. Sustainability and Environmental Impact - The company is committed to sustainable practices, aiming to reduce the environmental impact of its operations through innovative technologies[14]. - The company emphasizes the importance of ESG, integrating it into its core business operations, viewing it as a cornerstone for sustainable development[200]. - The company is actively pursuing low-carbon goals and aims to establish efficient, clean, and circular green factories[200]. - The company has implemented a management system audit and energy-saving certification to enhance operational efficiency[200]. Market Position and Growth Strategy - The anticipated growth in the municipal and industrial wastewater treatment sectors is expected to drive revenue growth in the coming years[15]. - The company is exploring strategic partnerships and potential acquisitions to bolster its market position and technological capabilities[16]. - The company aims to enhance its market position through continuous innovation and the development of proprietary technologies in the membrane sector[62]. - The company plans to leverage its experience and brand advantage in membrane technology to create a comprehensive membrane industry chain covering materials, components, equipment, software, and applications[139]. - The company will focus on international market expansion, particularly in Southeast Asia, by enhancing its sales team and recruiting talent[143]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 1,159, with 668 in production, 61 in sales, 224 in technology, and 45 in finance[188]. - The company has established a scientific and fair compensation mechanism based on job importance and scarcity, ensuring employee stability and satisfaction[190]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 478.48 million[171]. - The company has expanded its leadership team with individuals holding key positions across multiple subsidiaries, enhancing its operational capabilities[169]. Financial Management - The company plans to utilize remaining fundraising for permanent working capital after project completions[105]. - The company has adjusted the implementation content and postponed the Singapore R&D center project to March 2024 due to public health safety controls[103]. - The company has established a strict management system for subsidiaries, ensuring compliance with regulations and timely decision-making[198]. - The company has implemented a remuneration scheme for directors and senior management based on actual operating conditions[171].

2022 年第三季度报告 证券代码：688101 证券简称：三达膜 三达膜环境技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 LAN WEIGUANG、主管会计工作负责人唐佳菁及会计机构负责人（会计主管人 员）庄毅斌保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 307,118,640.10 | 4 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, reflecting an expected growth of 10%[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a 15% year-over-year growth[13]. - The company has set a future outlook with a revenue target of 2.5 billion RMB for the full year 2022, which would require a 10% increase in the second half[13]. - The gross profit margin for the first half of 2022 was reported at 45%, an increase from 40% in the same period last year[13]. - The company achieved operating revenue of CNY 441.81 million in the first half of 2022, an increase of 9.58% compared to the same period last year[19]. - Net profit attributable to shareholders decreased by 16.42% to CNY 111.72 million, primarily due to delays in project acceptance caused by the ongoing COVID-19 pandemic[19]. - The net profit after deducting non-recurring gains and losses was CNY 95.68 million, down 21.51% year-on-year[19]. - The net cash flow from operating activities increased by CNY 10.01 million, compared to a negative cash flow of CNY 8.18 million in the same period last year[19]. - The total assets of the company have increased to 3 billion RMB, reflecting a 12% growth compared to the previous year[13]. User Growth - User data indicates a growth in the customer base, with an increase of 20% in active users compared to the same period last year[1]. - User data indicates a growth in active users, with a 20% increase compared to the previous year, reaching 500,000 active users[13]. Product Development - New product development includes the launch of a high-efficiency membrane technology, projected to increase production capacity by 30%[1]. - New product development includes the introduction of a graphene membrane technology, which is expected to enhance water treatment efficiency by 30%[12]. - The company has invested RMB 50 million in R&D for new membrane materials, aiming for a 15% improvement in separation efficiency[1]. - The company is investing 100 million RMB in R&D for new filtration technologies over the next two years[12]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[12]. - A strategic acquisition of a local competitor is in progress, expected to enhance the company's technological capabilities and market reach[1]. - A strategic acquisition of a local water treatment firm is anticipated to be completed by Q3 2022, expected to add 300 million RMB in annual revenue[12]. Operational Efficiency - The company has implemented new operational strategies to improve cost efficiency, targeting a reduction in operational costs by 5%[1]. - The company aims to reduce operational costs by 15% through improved management practices and technology upgrades[12]. Research and Development - The company has established a "RDPA" R&D system focused on membrane technology applications, emphasizing the development and improvement of membrane materials and wastewater treatment processes[38]. - The company collaborates with government, universities, and research institutions to enhance its innovation capabilities and address common and key technologies in membrane material development[39]. - The company achieved a total R&D investment of ¥22,057,008.13, representing a 20.37% increase compared to ¥18,324,015.19 in the previous year[57]. - The total R&D investment accounted for 4.99% of the operating revenue, an increase of 0.45 percentage points from 4.54%[57]. - The company has a strong focus on expanding its R&D capabilities as a key competitive advantage[54]. Environmental Compliance - The company has established a comprehensive environmental management system to oversee its wastewater treatment operations across various regions[116]. - The company’s wastewater treatment facilities are equipped with advanced pollution control technologies to meet regulatory requirements[116]. - The company is committed to maintaining its status as a responsible environmental steward by adhering to all applicable pollution discharge standards[116]. - The company has implemented continuous monitoring and reporting of wastewater discharge metrics to maintain compliance with national standards[121]. Shareholder Commitments - The company has committed to not transferring or managing shares for 36 months post-IPO, ensuring stability in shareholding[132]. - The company reported a commitment to long-term holding of shares, indicating a positive outlook on the industry and the company's future development prospects[135]. - The company stated that during the lock-up period, it will not reduce its holdings in the company’s shares, adhering to legal and regulatory requirements[135]. - The company will ensure that any share reductions will not be below the initial offering price[135]. Legal and Regulatory Matters - The company received a regulatory warning from the Shanghai Stock Exchange regarding the improper use of raised funds, including using part of the excess funds for working capital without board approval[150]. - The company reported a civil lawsuit involving a contract dispute with a claim amount of ¥15,775,097.40, which was resolved through a mediation agreement[149]. - The company successfully appealed an administrative penalty, resulting in a court ruling that favored the company, which will positively impact its operations[149]. - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds and will improve its management practices[150].

Financial Performance - Operating revenue for Q1 2022 was CNY 164,304,322.88, an increase of 2.78% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 58,181,871.82, a decrease of 7.99% year-on-year[3] - Basic earnings per share for the period was CNY 0.17, down 8.28% from the previous year[4] - The weighted average return on equity was 1.68%, a decrease of 0.22 percentage points[4] - Net profit for Q1 2022 was ¥59.48 million, a decrease of 6.3% compared to ¥63.79 million in Q1 2021[20] - The company reported a total profit of ¥65.52 million in Q1 2022, down from ¥70.61 million in Q1 2021[20] Research and Development - R&D investment totaled CNY 10,169,998.91, representing 6.19% of operating revenue, an increase of 1.19 percentage points[4] - Research and development expenses rose to ¥10.17 million in Q1 2022, up 27.3% from ¥7.99 million in Q1 2021[19] Cash Flow and Liquidity - Net cash flow from operating activities was CNY 14,571,468.67, with a significant increase attributed to the commencement of several large-scale membrane technology projects[8] - Cash flow from operating activities generated a net inflow of ¥14.57 million in Q1 2022, compared to a net outflow of ¥33.74 million in Q1 2021[22] - Cash and cash equivalents were reported at CNY 824,765,526.69, down from CNY 1,231,756,309.30, representing a decrease of approximately 33%[15] - Cash and cash equivalents at the end of Q1 2022 were ¥812.91 million, down from ¥916.02 million at the end of Q1 2021[22] Assets and Liabilities - Total assets at the end of the period were CNY 4,917,615,979.17, an increase of 1.30% from the end of the previous year[4] - The company's total current assets reached CNY 2,918,169,336.98, compared to CNY 2,865,673,755.51 in the previous year, indicating an increase of about 1.8%[16] - The company's total liabilities stood at CNY 1,379,494,042.27, slightly up from CNY 1,375,985,512.15, showing a marginal increase of about 0.1%[17] - The total equity attributable to shareholders was CNY 3,492,640,608.52, an increase from CNY 3,434,458,736.70, reflecting a growth of approximately 1.7%[17] - The company's inventory increased to CNY 677,673,899.73 from CNY 591,767,853.70, marking a rise of about 14.5%[16] - The accounts receivable decreased slightly to CNY 559,366,463.44 from CNY 570,034,482.96, indicating a decline of approximately 1.8%[15] - The company’s non-current assets totaled CNY 1,999,446,642.19, a slight increase from CNY 1,988,958,222.42, reflecting a growth of about 0.5%[16] - The company’s total liabilities and equity amounted to CNY 4,917,615,979.17, consistent with the total assets reported[18] Shareholder Information - The total number of ordinary shareholders at the end of the period was 14,331[10] - The largest shareholder, Sanda Membrane Technology (Singapore) Co., Ltd., held 43.36% of the shares[11] Financial Standards and Governance - The company has implemented new accounting standards starting from 2022, affecting the financial statements from the beginning of the year[23] - The board of directors held a meeting on April 28, 2022, to discuss the quarterly report[24]

Financial Performance - The company achieved operating revenue of CNY 1,150,709,066.63 in 2021, representing a year-on-year growth of 31.29%[24]. - Net profit attributable to shareholders reached CNY 247,121,741.23, an increase of 11.41% compared to the previous year[24]. - The net profit after deducting non-recurring gains and losses grew by 18.67% year-on-year, amounting to CNY 218,456,469.44[24]. - Cash flow from operating activities increased significantly by 87.25%, totaling CNY 221,133,458.56[24]. - Basic earnings per share rose to CNY 0.74, reflecting a 12.12% increase from the previous year[25]. - The company's total assets at the end of 2021 were CNY 4,854,631,977.93, a 7.09% increase from the end of 2020[24]. - The weighted average return on equity improved to 7.40%, up by 0.53 percentage points from the previous year[25]. - The company reported a significant increase in investment income from joint ventures compared to the previous year, contributing to the net profit growth[27]. Research and Development - The company is investing in research and development, with a budget allocation of approximately $5 million for the development of advanced water treatment technologies[16]. - Research and development expenses accounted for 4.54% of operating revenue, slightly down from 4.58% in 2020[25]. - The total R&D investment for the year was approximately ¥52.21 million, representing a 30.16% increase compared to the previous year[75]. - The company applied for a total of 35 patents during the reporting period, with 26 patents granted, including 7 invention patents and 19 utility model patents[73]. - The company has developed a comprehensive "RDPA" research and development system focused on membrane technology applications, enhancing its core competitiveness[53]. Market Expansion and Strategy - The company is expanding its market presence in seawater desalination, targeting coastal regions to provide fresh water for residential and industrial use[15]. - The company has set a revenue growth target of 15% for the upcoming fiscal year, driven by new product launches and market expansion initiatives[16]. - The company is actively pursuing strategic partnerships and acquisitions to enhance its technological capabilities and market reach[16]. - The company is expanding its production bases across five locations, including Fujian, to alleviate capacity pressure at the Xiamen facility[35]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[158]. Technological Innovation - The company reported a significant focus on membrane technology, including microfiltration, ultrafiltration, nanofiltration, and reverse osmosis, which are essential for water treatment processes[14]. - The company has developed a new graphene membrane technology aimed at enhancing water purification efficiency and reducing operational costs[15]. - The company has innovated various advanced inorganic non-metallic membrane materials and high-performance composite membranes, which can replace imported products and offer superior performance[45]. - The company has established a postdoctoral research station and a provincial membrane separation engineering technology center, focusing on membrane separation technology and new membrane material development since 2002[89]. Corporate Governance and Compliance - The company has not reported any violations of decision-making procedures regarding external guarantees[9]. - The company has received a standard unqualified audit report from the accounting firm[8]. - The internal control system is in place and has been evaluated without significant deficiencies during the reporting period[193]. - The company emphasizes the protection of minority shareholders' rights through its clear and transparent dividend distribution process[189]. - The company has updated its articles of association in accordance with the latest laws and regulations, strengthening the responsibilities of independent directors[197]. Environmental Responsibility - The company is committed to achieving compliance with environmental standards, aiming for a 20% reduction in pollutant discharge from its operations by the end of the next fiscal year[16]. - The company operates multiple key pollutant discharge units across various provinces, including Henan, Hubei, Fujian, and Jiangxi, ensuring compliance with local environmental standards[198]. - The company’s wastewater treatment plants have specific discharge limits, such as CODcr ≤ 912.5 tons/year and ammonia nitrogen ≤ 146 tons/year for Xiaogan San Da Water Co., Ltd.[199]. - The company integrates ESG principles into its business strategy, focusing on sustainable development and environmental responsibility[196]. Shareholder and Investor Relations - The company plans to use part of the raised funds to permanently supplement working capital, as approved in the first temporary shareholder meeting[148]. - The company established good investor relations through various communication channels, including investor calls and website interactions[145]. - All resolutions from the four shareholder meetings held during the reporting period were approved without any rejections[149]. - The company is committed to maintaining transparency in its financial dealings and has adhered to relevant policies regarding shareholding[152]. Operational Efficiency - The company reported a 30% increase in operational efficiency due to the implementation of continuous ion exchange technology in its processes[15]. - The company has implemented upgrades and expansions in its water investment operations, applying membrane technology in several wastewater treatment plants, enhancing both treatment standards and revenue[44]. - The company has established stable partnerships with several domestic and international suppliers for raw materials, ensuring a reliable procurement process[47]. Risks and Challenges - The company faces risks related to technological upgrades and the need for continuous innovation to remain competitive in the membrane technology application industry[92]. - The company is exposed to accounts receivable risks due to slow sales returns and long account aging, particularly in its water investment and operation business[93]. - The ongoing COVID-19 pandemic continues to pose uncertainties that may affect client contracts and marketing budgets[97]. - The company is facing intensified competition in the membrane technology application industry due to the entry of large foreign firms[96].

Financial Performance - The company's operating revenue for Q3 2021 was CNY 294,413,320.57, representing a year-on-year increase of 50.22%[5] - The net profit attributable to shareholders for Q3 2021 was CNY 76,232,123.29, an increase of 21.35% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses for Q3 2021 was CNY 69,702,880.52, up 32.53% year-on-year[6] - The company's revenue for the year-to-date period was CNY 697,589,749.03, representing a year-on-year increase of 31.96%[5] - The net profit attributable to shareholders for the year-to-date period was CNY 209,901,204.39, reflecting a growth of 24.26% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 reached ¥697,589,749.03, a 32% increase from ¥528,635,459.19 in the same period of 2020[21] - Net profit for the third quarter of 2021 was ¥211,512,701.16, compared to ¥170,850,786.25 in the same quarter of 2020, representing a 24% increase[22] - Earnings per share (EPS) for the third quarter was ¥0.63, up from ¥0.51 in the previous year[23] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period reached CNY 47,957,229.66, showing a significant increase of 186.81%[6] - The company's cash and cash equivalents as of September 30, 2021, amount to ¥941,390,982.50, down from ¥1,193,976,534.34 as of December 31, 2020, reflecting a decrease of approximately 21%[16] - The company's cash and cash equivalents at the end of the third quarter were not disclosed, but the increase in net profit suggests improved liquidity[22] - The company's operating cash flow for the first three quarters of 2021 was ¥47,957,229.66, a significant increase from ¥16,721,032.34 in the same period of 2020, representing a growth of approximately 187.5%[24] - Cash and cash equivalents at the end of the period stood at ¥924,775,074.44, down from ¥878,198,581.25 in the same period last year[25] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to CNY 4,621,078,733.74, reflecting a growth of 1.94% compared to the end of the previous year[6] - The company's total liabilities as of the end of the third quarter were ¥1,136,510,960.98, a slight decrease from ¥1,193,271,407.12 at the end of the previous year[19] - The total equity attributable to shareholders increased to ¥3,443,330,091.67 from ¥3,300,204,887.28, marking a growth of approximately 4.3%[19] - Total cash inflow from investment activities decreased to ¥958,003,835.63 in 2021 from ¥2,558,444,228.87 in 2020, indicating a decline of about 62.5%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,841[13] - The largest shareholder, Sanda Membrane Technology (Singapore) Co., Ltd., holds 144,770,450 shares, representing 43.36% of total shares[13] - The company has a total of 85,682,350 unrestricted circulating shares held by Qingyuan (China) Co., Ltd.[14] Research and Development - Research and development expenses totaled CNY 10,922,897.89 for Q3 2021, accounting for 3.71% of operating revenue, a decrease of 1 percentage point year-on-year[6] - Research and development expenses for the first three quarters were ¥29,246,913.08, compared to ¥24,774,176.48 in the same period of 2020, indicating a 18% increase[21] Investment Activities - Investment income for the third quarter was ¥55,080,979.21, significantly higher than ¥29,812,181.29 in the same quarter of the previous year[22] - The net cash flow from investment activities was negative at -¥336,845,649.57, compared to a positive cash flow of ¥82,288,269.54 in the previous year[25] Operational Costs - Total operating costs amounted to ¥521,029,183.33, up from ¥385,592,448.23, reflecting a 35% increase year-over-year[21] Future Outlook - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1]. - The net profit attributable to shareholders reached RMB 15 million, up 25% compared to the same period last year[1]. - The company achieved operating revenue of CNY 403.18 million in the first half of the year, representing a year-on-year increase of 21.20% compared to CNY 332.65 million in the same period last year[21]. - Net profit attributable to shareholders reached CNY 133.67 million, up 25.99% from CNY 106.10 million in the previous year[22]. - The basic earnings per share increased to CNY 0.40, reflecting a growth of 25.00% compared to CNY 0.32 in the same period last year[20]. - The company reported a total profit for the first half of 2021 of CNY 151,026,381.78, compared to CNY 122,412,638.59 in the previous year, representing an increase of approximately 23.3%[167]. - The total comprehensive income for the first half of 2021 was CNY 134,723,068.67, compared to CNY 107,359,957.50 in the previous year, indicating an increase of about 25.5%[168]. - The company reported a net profit margin improvement, with net profit for the first half of 2021 expected to be higher than the previous year, although specific figures were not disclosed[165]. Research and Development - The company is investing RMB 10 million in R&D for new membrane technologies aimed at enhancing separation efficiency[1]. - The company’s R&D investment accounted for 4.54% of operating revenue, slightly down from 4.67% in the previous year[20]. - The total R&D investment amounted to ¥18,324,015.19, representing a 17.87% increase compared to the previous period[60]. - The company has a total of 136 valid patents, including 73 invention patents and 62 utility model patents as of June 30, 2021[59]. - The company has developed multiple leading products in membrane materials, including nanofiltration membranes, ceramic membranes, and hollow fiber membranes, which are essential for industrial liquid separation and water treatment[29]. - The company has developed innovative membrane separation processes, filling multiple gaps in domestic and international membrane application technologies, particularly in the pharmaceutical and food industries[50]. - The company has established a comprehensive technology development platform based on a "target-oriented, reverse thinking" R&D principle, enhancing its core competitiveness[57]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 15% for the second half of 2021, driven by new product launches and market expansion strategies[1]. - The company has expanded its user base by 30%, now serving over 500,000 customers[1]. - Market expansion efforts include entering two new regional markets, expected to contribute an additional RMB 5 million in revenue[1]. - The company aims to expand its market presence through strategic partnerships and technological innovations in water treatment solutions[12]. - The company plans to continue expanding its market presence and enhancing its product offerings in membrane technology applications and water investment operations[27]. - The company is actively expanding its market presence by monitoring government project approvals and leveraging existing operational efficiencies in regions where it has established projects[42]. Environmental Compliance and Sustainability - The company operates multiple key pollutant discharge units across various provinces, including Henan, Hubei, Fujian, Jiangxi, Anhui, and Jilin, indicating a significant environmental footprint[101]. - The company reported no instances of exceeding the approved pollutant discharge limits across its facilities, demonstrating compliance with environmental regulations[101]. - The company is committed to maintaining compliance with environmental standards, including a total nitrogen limit of ≤369.5625 tons/year and total phosphorus limit of ≤12.31875 tons/year for one of its plants[106]. - The company has established and is operating pollution prevention facilities that have passed environmental acceptance by local authorities[109]. - The company has developed emergency response plans for sudden environmental incidents, ensuring rapid and effective responses to potential pollution events[111]. Financial Position and Cash Flow - The company has maintained a strong cash position with RMB 50 million in cash reserves, ensuring liquidity for future investments[1]. - The company reported a significant increase in cash flow from investment activities, with a net cash inflow of 12.31 million yuan, compared to a net outflow of 125.15 million yuan in the previous year[81]. - The company’s total assets decreased by 1.59% to CNY 4.46 billion from CNY 4.53 billion at the end of the previous year[22]. - The company’s total assets as of June 30, 2021, were ¥3,146,024,312.11, slightly up from ¥3,131,123,818.99 at the end of 2020[164]. - The company’s cash flow from operating activities improved significantly, with a net outflow of 8.18 million yuan, an improvement of 41.61% compared to the previous year[81]. - The ending balance of cash and cash equivalents was 1,158,433,240.98 RMB, compared to 643,618,006.62 RMB at the end of the first half of 2020, showing an increase of approximately 80%[175]. Corporate Governance and Shareholder Commitments - The company has committed to not transferring or managing shares for a period of 36 months post-IPO, ensuring stability in shareholding[115]. - The company will not sell shares below the initial public offering price, with adjustments made for any dividends or capital increases prior to the sale[121]. - The company’s controlling shareholder and actual controllers promised to avoid any direct or indirect competition with the company and its subsidiaries[125]. - The company will minimize or avoid related party transactions, adhering to market rules and ensuring fairness and transparency in necessary transactions[127]. - The company’s commitment to avoid competition is irrevocable and will remain effective during the tenure of the controlling shareholders[126].

Financial Performance - Operating revenue for the period reached CNY 159.87 million, representing a year-on-year increase of 19.49%[5] - Net profit attributable to shareholders was CNY 63.23 million, an increase of 8.43% compared to the same period last year[5] - Basic and diluted earnings per share were both CNY 0.19, an increase of 11.76% compared to the previous year[5] - Total operating revenue for Q1 2021 was CNY 159,865,970.07, an increase of 19.5% compared to CNY 133,788,301.28 in Q1 2020[24] - The net profit for Q1 2021 reached CNY 10,329,221.05, representing a 16.3% increase compared to CNY 8,878,547.33 in Q1 2020[28] - The total profit for Q1 2021 was CNY 11,640,621.96, compared to CNY 9,333,201.50 in Q1 2020, marking a 24.7% increase[28] Cash Flow - The net cash flow from operating activities was negative CNY 33.74 million, worsening by 50.26% year-on-year[5] - The cash flow from operating activities for Q1 2021 was CNY 143,718,366.16, an increase from CNY 126,099,645.87 in Q1 2020[30] - The net cash flow from operating activities for Q1 2021 was -33,737,697.76 RMB, compared to -22,452,386.62 RMB in Q1 2020, indicating a decline in operational cash flow[31] - Total cash inflow from investment activities was 100,227,945.21 RMB, significantly lower than 706,388,309.69 RMB in the previous year, reflecting reduced investment recovery[31] - The net cash flow from investment activities was -226,279,410.27 RMB, compared to -213,597,442.94 RMB in Q1 2020, showing a continued outflow trend[31] - The total cash outflow from financing activities was 2,665,748.91 RMB, compared to 22,274,448.68 RMB in the previous year, indicating a significant reduction in financing outflows[32] Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 4.53 billion, a decrease of 0.03% compared to the end of the previous year[5] - The total assets as of March 31, 2021, were RMB 4,531,955,561.93, slightly down from RMB 4,533,102,478.72 as of December 31, 2020[18] - Total liabilities as of March 31, 2021, were CNY 1,128,336,951.80, down from CNY 1,193,271,407.12 at the end of 2020[20] - Current liabilities totaled CNY 727,290,522.61, a decrease of 9.1% from CNY 800,692,336.08 in the previous period[20] - Shareholders' equity increased to CNY 3,403,618,610.13 as of March 31, 2021, compared to CNY 3,339,831,071.60 at the end of 2020[20] Research and Development - The R&D investment accounted for 5.00% of operating revenue, up from 4.86% in the previous year[5] - R&D expenses for Q1 2021 amounted to CNY 7,990,682.42, representing an increase of 22.8% from CNY 6,504,689.88 in Q1 2020[24] - Research and development expenses increased to CNY 4,515,127.79 in Q1 2021, compared to CNY 3,860,405.61 in Q1 2020, reflecting a 17% rise[27] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,598[11] - The largest shareholder, Sanda Membrane Technology (Singapore) Co., Ltd., held 43.36% of the shares[11] Financial Position - The company's cash and cash equivalents amounted to RMB 941,691,635.66, down from RMB 1,193,976,534.34 as of December 31, 2020, indicating a decrease of approximately 21.06%[17] - Cash and cash equivalents decreased to CNY 759,294,232.19 from CNY 1,025,321,405.86 at the end of 2020, indicating a liquidity contraction[21] - Cash and cash equivalents at the end of Q1 2021 stood at 916,024,351.50 RMB, down from 650,135,820.04 RMB in Q1 2020[32] Other Financial Metrics - The weighted average return on equity increased by 0.07 percentage points to 1.90%[5] - The company's financial expenses decreased by 56.56% to RMB 1,091,778.73 from RMB 2,513,306.32, due to increased interest income and reduced interest expenses from lower borrowings[14] - The fair value changes in financial assets resulted in a loss of RMB 3,431,506.85, down 53.3% from RMB 7,347,811.24 in the previous year[14] - The company incurred credit impairment losses of CNY 5,218,244.76 in Q1 2021, compared to CNY 1,577,342.82 in Q1 2020, indicating a significant rise in credit risk[27]

Financial Performance - The company achieved operating revenue of CNY 876,447,101.03 in 2020, representing an increase of 18.12% compared to the previous year[24]. - Net profit attributable to shareholders decreased by 19.82% to CNY 221,805,911.11, primarily due to reduced investment income from joint ventures[22]. - The net cash flow from operating activities fell by 50.03% to CNY 118,098,323.81, largely impacted by the pandemic[24]. - Total assets increased by 7.16% to CNY 4,533,102,478.72 at the end of 2020[22]. - Basic earnings per share decreased by 38.32% to CNY 0.66 in 2020[23]. - The weighted average return on equity dropped by 9.53 percentage points to 6.87%[23]. - The company reported a quarterly revenue of CNY 347,811,641.84 in Q4 2020, the highest among the quarters[26]. - The company reported a total profit of CNY 37,716,252.07 for the year, a significant increase from CNY 6,946,929.07 in the previous year, representing a growth of approximately 442%[30]. Dividend Policy - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, totaling 66,776,000 RMB, which represents 30.11% of the net profit attributable to shareholders for 2020[5]. - The cash dividend policy stipulates a minimum distribution of 30% of distributable profits for the year, after covering losses and legal reserves[136]. - The company has established a differentiated cash dividend policy based on its development stage, with a minimum cash dividend ratio of 80% for mature stages without major capital expenditures[135]. - The cash dividend distribution plan has been approved by the board and requires shareholder meeting approval for implementation[138]. - The company has maintained compliance with its cash dividend principles and policies, ensuring transparency and protection of minority shareholders' rights[138]. Research and Development - The company has developed advanced inorganic non-metal membrane materials and high-performance composite membrane materials, establishing a comprehensive membrane industry chain[34]. - The company’s investment in research and development has led to industry-leading positions in multiple membrane products, including nanofiltration cores and hollow fiber membranes[36]. - The company has established a "RDPA" research and development system focused on membrane technology applications, emphasizing a comprehensive technical development platform for research, development, pilot testing, and application[49]. - R&D investment totaled approximately ¥40.12 million, representing a 1.77% increase from the previous year, with R&D expenses accounting for 4.58% of operating revenue, down from 5.31%[68]. - The total R&D personnel count has increased to 198, representing 19.04% of the total workforce, with an average salary of 143,648.36 RMB[79]. Operational Risks and Compliance - The company has outlined various operational risks and corresponding mitigation measures in the report[4]. - The report includes a standard unqualified audit opinion from the accounting firm Rongcheng[4]. - There are no non-operational fund occupations by controlling shareholders or related parties reported[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company has not reported any significant accounting errors or changes in accounting policies that would impact its financial statements[153]. Environmental Commitment - The annual report highlights the company's commitment to clean production methods, aiming to reduce pollution and improve resource utilization efficiency[12]. - The company operates multiple wastewater treatment plants, adhering to the Class A and Class B standards of the "Urban Wastewater Treatment Plant Pollutant Discharge Standards" (GB18918-2002) with specific discharge limits for CODcr, ammonia nitrogen, total nitrogen, and total phosphorus[189][190]. - The company has established emergency response plans for sudden environmental incidents, ensuring rapid and effective responses to potential pollution events[194]. - The company has no reported incidents of non-compliance with pollutant discharge standards across its facilities[189][190]. Market Position and Strategy - Future outlook includes expanding market presence and exploring potential mergers and acquisitions to strengthen competitive positioning[12]. - The company has a market share exceeding 60% in the petrochemical PTA sector, indicating a leading position in water treatment business[84]. - The company is focusing on the development of new products and technologies to enhance market competitiveness and expand into new markets[72]. - The company is committed to becoming a global leader in membrane technology development and application, focusing on sustainable manufacturing and clean production[128]. Related Party Transactions - The company has committed to minimizing or avoiding related party transactions, ensuring compliance with market rules and fair practices[154]. - The company engaged in a related party lease transaction with San Da Membrane Technology Park Development (Xiamen) Co., Ltd., with an expected amount of RMB 240 million and an actual amount of RMB 249.82 million[159]. - The company has retained Rongcheng Accounting Firm for the 2020 financial and internal control audit, with a remuneration of RMB 1,200,000[154]. Future Investments and Projects - The company plans to invest raised funds in projects related to inorganic ceramic nanofiltration membranes and water purification systems, which may take time to yield economic benefits[100]. - The company is currently developing several projects, including a composite nanofiltration membrane with an expected total investment of ¥2.5 million, with a current investment of approximately ¥1.23 million[71]. - The company has obtained the necessary administrative approvals for overseas investment related to the membrane materials and technology R&D center project[179].